FTSE 100 news / Companies and sectors / GSK / 30 September 2026
GSK (GSK): news on Wednesday 30 September 2026
+8.7 strongly positive
Coverage was mostly positive, led by Jefferies keeping its buy rating and Berenberg setting a 2,200p target, with attention on the B7H3 cancer programme. GSK's return to China in blood cancer drugs and an FDA agenda slot for its hepatitis B candidate added to the upbeat tone.
What drove it
- analyst upgrades and targets
- B7H3 cancer programme
- China return
The 7 stories
- +10.0 Jefferies keeps buy on GSK, sees 35% upside on promising B7H3 cancer drug program
Jefferies keeps buy, sees 35% upside on cancer programme. - +10.0 GSK retains ‘buy’ rating at Jefferies as B7H3 cancer programme seen as underappreciated
Jefferies buy rating; B7H3 programme seen as underappreciated. - +8.3 Re-entering the Dragon: GSK returns to China after 12 years in blood cancer drug push
Return to China in blood cancer drugs signals expansion. - +7.5 GSK stock gets a GBp 2,200.00 target from Berenberg
Berenberg sets a price target of 2,200p. - +6.7 Spotlight On: GSK's HBV hopeful tops FDA's October agenda
Hepatitis B drug candidate features on FDA's October agenda. - +4.2 HutchMed puts GSK-partnered KRAS-EGFR conjugate into Phase I in China
Partnered cancer candidate advances into Phase I trials. - +2.5 TV star speaks out for GSK campaign
Awareness campaign with celebrity backing; mildly positive profile.
GSK: every day · Pharma and healthcare on 30 September 2026 · FTSE 100 overview for the day